Skip to main content
Home
Zeitschriften
Zeitungen
Podcast
Gesundheitspolitik
Praxis
Allerlei
Jobs
Fachgebiete
Allgemeinmedizin Anästhesiologie & Intensivmedizin Apotheke Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kinder & Jugendheilkunde Neurologie & Psychiatrie Orthopädie & Unfallchirurgie Pflege Urologie Zahnmedizin
Subfächer Innere Medizin
Diabetologie Gastroenterologie Infektiologie Kardiologie Onkologie und Hämatologie Pneumologie Rheumatologie
Fortbildungen
Überblick Fortbildungen DFP-Literaturstudium-Artikel DFP-Webcast Fortbildungen DFP-Podcasts
Erweiterte Suche
Anmelden
nach oben
Wiener Medizinische Wochenschrift
Erschienen in:

01.05.2017 | main topic

Mechanisms on spasmolytic and anti-inflammatory effects of a herbal medicinal product consisting of myrrh, chamomile flower, and coffee charcoal

verfasst von: Dr. Cica Vissiennon, Karl-Heinz Goos, Jürgen Arnhold, Karen Nieber

Erschienen in: Wiener Medizinische Wochenschrift | Ausgabe 7-8/2017

Einloggen, um Zugang zu erhalten

Summary

Inflammatory bowel disease or irritable bowel syndrome are chronic gastrointestinal disorders which are associated with a lifelong therapeutic need. The disease results in physical, psychological, and social problems with an impact on partnership, sexuality, education, and career. Thus, the number of patients and health care professionals relying on traditional and complementary medicines and especially phytotherapy for the treatment of these chronic conditions is increasing over recent years. One traditional herbal medicinal product consisting of chamomile flower, myrrh, and coffee charcoal has been widely used in clinical practice within this indication area. Long-term experience and an increasing understanding of the pharmacological mechanisms substantiate its application and clinical effectiveness. Mainly the spasmolytic and anti-inflammatory effects provide a rationale for its therapeutic application. In addition, synergistic effects between the herbal components contribute to the overall effect of this medication.
Vorheriger Artikel Modulation of gastrointestinal motility beyond metoclopramide and domperidone
Nächster Artikel Randomized double-blind controlled clinical trials with herbal preparations of Serenoa repens fruits in treatment of lower urinary tract symptoms
Literatur
1.
Vind I, et al. Increasing incidences of inflammatory bowel disease and decreasing surgery rates in Copenhagen City and County, 2003–2005: a population-based study from the Danish Crohn colitis database. Am J Gastroenterol. 2006;101(6):1274–82.CrossRefPubMed
2.
Sina C, et al. The German competence network inflammatory bowel disease (KNCED) – network research leads to the identification of the cause of disease and to the improvement in patient care. Med Klin (Munich). 2006;101(2):161–5.CrossRef
3.
Knoflach P. Chronisch entzündliche Darmerkrankungen: Neues zur Ätiopathogenese. J Gastroenterol Hepatol Erkrank. 2014;12(3):7–10.
4.
5.
Mahida YR. The key role of macrophages in the immunopathogenesis of inflammatory bowel disease. Inflamm Bowel Dis. 2000;6(1):21–33.CrossRefPubMed
6.
7.
Moser G. Bedeutung von Stress und Depression bei chronisch entzündlichen Darmerkrankungen. J Gastroenterol Hepatol Erkrank. 2015;3(2):26–30.
8.
Langhorst J, et al. Systematic review of complementary and alternative medicine treatments in inflammatory bowel diseases. J Crohns Colitis. 2015;9(1):86–106.CrossRefPubMed
9.
Hilsden RJ, et al. Use of complementary and alternative medicine by patients with Inflammatory Bowel Disease. Inflamm Bowel Dis. 2011;17(2):655–62.CrossRefPubMed
10.
Ng SC, et al. Systematic review: the efficacy of herbal therapy in inflammatory bowel disease. Aliment Pharmacol Ther. 2013;38(8):854–63.CrossRefPubMed
11.
Wagner H. Multitarget therapy – the future of treatment for more than just functional dyspepsia. Phytomedicine. 2006;13:122–9.CrossRefPubMed
12.
Albrecht U, et al. Efficacy and safety of a herbal medicinal product containing myrrh, chamomile and coffee charcoal for the treatment of gastrointestinal disorders: a non-interventional study. BMJ Open Gastroenterol. 2014;1(1):e000015. doi:10.​1136/​bmjgast-2014-000015.CrossRefPubMed
13.
Stange R, et al. Günstiger Verlauf einer schweren Colitis ulcerosa. Forsch Komplementmed. 2004;5(6):296–9.CrossRef
14.
Gruia FS. Das Phytotherapeutikum Myrrhinil-Intest® bei unspezifischen Darmerkrankungen. Erfahrungsheilkunde. 1987;2:77–82.
15.
Langhorst J, et al. Randomised clinical trial: a herbal preparation of myrrh, chamomile and coffee charcoal compared with mesalazine in maintaining remission in ulcerative colitis – a double-blind, double-dummy study. Aliment Pharmacol Ther. 2013;38(5):490–500.CrossRefPubMed
16.
Malykhina AP, Akbarali HI. Inflammation-induced “channelopathies” in the gastrointestinal smooth muscle. Cell Biochem Biophys. 2004;41(2):319–30.CrossRefPubMed
17.
Srinath AI, et al. Pain management in patients with inflammatory bowel disease: insights for the clinician. Therap Adv Gastroenterol. 2012;5(5):339–57.CrossRefPubMedPubMedCentral
18.
Vissiennon C. In vitro studies on the mechanisms of action of chamomile, myrrh and coffee charcoal: components of a traditional herbal medicinal product (Myrrhinil-Intest®). Dissertation. Leipzig: Universität Leipzig; 2014.
19.
Pumnea T, et al. The herbal extracts of Myrrh, Chamomile and Coffee Charcoal modulate intestinal neurotransmission and motility in murine small intestine. Phytomedicine in preparation
20.
Schilcher H. Die Kamille. Handbuch für Ärzte, Apotheker und andere Naturwissenschaftler. Stuttgart: Wissenschaftliche Verlagsgesellschaft; 1987.
21.
Achterrath-Tuckermann U, et al. Pharmakologische Untersuchungen von Kamillen-Inhaltsstoffen. Planta Med. 1980;39(05):38–50.CrossRefPubMed
22.
Mehmood MH, et al. Antidiarrhoeal, antisecretory and antispasmodic activities of Matricaria chamomilla are mediated predominantly through K(+)-channels activation. BMC Complement Altern Med. 2015;15:75.CrossRefPubMedPubMedCentral
23.
Sebai H, et al. Antidiarrheal and antioxidant activities of chamomile (Matricaria recutita L.) decoction extract in rats. J Ethnopharmacol. 2014;152(2):327–32.CrossRefPubMed
24.
Vissiennon C, et al. Calcium antagonistic effects of ethanolic myrrh extract in inflamed intestinal smooth muscle preparations. Planta Med. 2013; doi:10.​1055/​s-0033-1351895.
25.
Rogler G, Andus T. Cytokines in inflammatory bowel disease. World J Surg. 1998;22(4):382–9.CrossRefPubMed
26.
Al-Hindawi MK, et al. Anti-inflammatory activity of some Iraqi plants using intact rats. J Ethnopharmacol. 1989;26(2):163–8.CrossRefPubMed
27.
Gerritsen ME, et al. Flavonoids inhibit cytokine-induced endothelial cell adhesion protein gene expression. Am J Pathol. 1995;147(2):278.PubMedPubMedCentral
28.
Della Loggia R, et al. Evaluation of the anti-inflammatory activity of chamomile preparations. Planta Med. 1990;56(06):657–8.CrossRef
29.
Tubaro A, et al. Evaluation of antiinflammatory activity of a chamomile extract topical application. Planta Med. 1984;50(4):359.CrossRef
30.
Bhaskaran N, et al. Chamomile: an anti-inflammatory agent inhibits inducible nitric oxide synthase expression by blocking RelA/p65 activity. Int J Mol Med. 2010;26(6):935–40.PubMedPubMedCentral
31.
Menghini L, et al. An hydroalcoholic chamomile extract modulates inflammatory and immune response in HT29 cells and isolated rat colon. Phytother Res. 2016;30(9):1513–8.CrossRefPubMed
32.
Srivastava JK, Pandey M, Gupta S. Chamomile, a novel and selective COX-2 inhibitor with anti-inflammatory activity. Life Sci. 2009;85(19–20):663–9.CrossRefPubMedPubMedCentral
33.
Ammon HP, Sabieraj J, Kaul R. Kamille. Mechanismus der antiphlogistischen Wirkung von Kamillenextrakten und -inhaltsstoffen. Dtsch Apoth Ztg. 1996;136:1821–34.
34.
Rocha NFM, et al. Anti-nociceptive and anti-inflammatory activities of (−)-alpha-bisabolol in rodents. Naunyn Schmiedebergs Arch Pharmacol. 2011;384(6):525–33.CrossRefPubMed
35.
Vissiennon C, et al. Chamomile flower, myrrh and coffee charcoal, components of a traditional herbal medicinal product, diminish pro-inflammatory activation in human macrophages. Z Phytother. 2016. doi:10.​1055/​s-0036-1584491.
36.
Su S, et al. Anti-inflammatory and analgesic activity of different extracts of Commiphora myrrha. J Ethnopharmacol. 2011;134(2):251–8.CrossRefPubMed
37.
Su S, et al. Evaluation of the anti-inflammatory and analgesic properties of individual and combined extracts from Commiphora myrrha, and Boswellia carterii. J Ethnopharmacol. 2012;139(2):649–56.CrossRefPubMed
38.
Tariq M, et al. Anti-inflammatory activity of Commiphora molmol. Agents Actions. 1986;17(3–4):381–2.CrossRefPubMed
39.
Atta AH, Alkofahi A. Anti-nociceptive and anti-inflammatory effects of some Jordanian medicinal plant extracts. J Ethnopharmacol. 1998;60(2):117–24.CrossRefPubMed
40.
Shalaby MA, Hammouda AA-E. Analgesic, anti-inflammatory and anti-hyperlipidemic activities of Commiphora molmol extract (Myrrh). J Intercult Ethnopharmacol. 2014;3(2):56–62.CrossRefPubMedPubMedCentral
41.
Fatani AJ, et al. Myrrh attenuates oxidative and inflammatory processes in acetic acid-induced ulcerative colitis. Exp Ther Med. 2016;12(2):730–8.PubMedPubMedCentral
42.
Tipton DA, et al. In vitro cytotoxic and anti-inflammatory effects of myrrh oil on human gingival fibroblasts and epithelial cells. Toxicol In Vitro. 2003;17(3):301–10.CrossRefPubMed
43.
Tipton DA, Hamman NR, Dabbous MK. Effect of myrrh oil on IL-1beta stimulation of NF-kappaB activation and PGE(2) production in human gingival fibroblasts and epithelial cells. Toxicol In Vitro. 2006;20(2):248–55.CrossRefPubMed
44.
Kim M‑S, et al. Myrrh inhibits LPS-induced inflammatory response and protects from cecal ligation and puncture-induced sepsis. Evid Based Complement Alternat Med. 2012;2012(3):1–11.
45.
Karp LC, Shanahan F, Targan SR. (editors) Inflammatory bowel disease. From bench to bedside. Norwell: Springer; 2005.
46.
Koshihara Y, et al. Caffeic acid is a selective inhibitor for leukotriene biosynthesis. Biochim Biophys Acta. 1984;792(1):92–7.CrossRefPubMed
47.
Nardini M, et al. In vitro inhibition of the activity of phosphorylase kinase, protein kinase C and protein kinase A by caffeic acid and a procyanidin-rich pine bark (Pinus marittima) extract. Biochim Biophys Acta. 2000;1474(2):219–25.CrossRefPubMed
48.
Feng R, et al. Inhibition of activator protein-1, NF-kappaB, and MAPKs and induction of phase 2 detoxifying enzyme activity by chlorogenic acid. J Biol Chem. 2005;280(30):27888–95.CrossRefPubMed
49.
Yang WS, et al. IRAK1/4-targeted anti-inflammatory action of caffeic acid. Mediators Inflamm. 2013;2013(1):1–12.
50.
Bone K, Mills S. Principles of herbal pharmacology. In: Bone K, Mills S, editors. Principles and practice of phytotherapy. Amsterdam: Elsevier; 2013. pp. 17–82.
51.
Berenbaum MC. What is synergy? Pharmacol Rev. 1989;41(2):93–141.PubMed
52.
Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 1984;22:27–55.CrossRefPubMed
53.
Fu J, et al. Drug combination in vivo using combination index method. Taxotere and T607 against colon carcinoma HCT-116 xenograft tumor in nude mice. Synergy. 2016;3(3):15–30.CrossRef
54.
Vissiennon C, et al. Synergistic interactions of chamomile flower, myrrh and coffee charcoal in inhibiting pro-inflammatory chemokine release from activated human macrophages. Synergy, in preparation
55.
Kopydlowski KM, et al. Regulation of macrophage chemokine expression by lipopolysaccharide in vitro and in vivo. J Immunol. 1999;163(3):1537–44.PubMed
56.
Berkman N, et al. Inhibition of macrophage inflammatory protein-1 alpha expression by IL-10. Differential sensitivities in human blood monocytes and alveolar macrophages. J Immunol. 1995;155(9):4412–8.PubMed
57.
Carlsen HS, et al. Monocyte-like and mature macrophages produce CXCL13 (B cell-attracting chemokine 1) in inflammatory lesions with lymphoid neogenesis. Blood. 2004;104(10):3021–7.CrossRefPubMed
58.
Ansel K, Cyster JG. Chemokines in lymphopoiesis and lymphoid organ development. Curr Opin Immunol. 2001;13(2):172–9.CrossRefPubMed
Metadaten
Titel
Mechanisms on spasmolytic and anti-inflammatory effects of a herbal medicinal product consisting of myrrh, chamomile flower, and coffee charcoal
verfasst von
Dr. Cica Vissiennon
Karl-Heinz Goos
Jürgen Arnhold
Karen Nieber
Publikationsdatum
01.05.2017
Verlag
Springer Vienna
Erschienen in
Wiener Medizinische Wochenschrift / Ausgabe 7-8/2017
Print ISSN: 0043-5341
Elektronische ISSN: 1563-258X
DOI
https://doi.org/10.1007/s10354-016-0538-y

Weitere Artikel der Ausgabe 7-8/2017

60 years of Cimicifuga racemosa medicinal products

  • Open Access
  • main topic

Clinical trial shows lasting function of a new moisturizing cream against vaginal dryness

  • main topic

Randomized double-blind controlled clinical trials with herbal preparations of Serenoa repens fruits in treatment of lower urinary tract symptoms

  • main topic

Herbal medicinal products and phytotherapy—a thematic issue

  • editorial

Modulation of gastrointestinal motility beyond metoclopramide and domperidone

  • Open Access
  • main topic

Ethanol in herbal medicinal products for children

  • Open Access
  • themenschwerpunkt